Warner Chilcott PLC Stock Downgraded (WCRX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK (TheStreet) -- Warner Chilcott (Nasdaq:WCRX) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and weak operating cash flow.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Highlights from the ratings report include:

• The gross profit margin for WARNER CHILCOTT PLC is currently very high, coming in at 90.60%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 8.30% trails the industry average.
• Regardless of the drop in revenue, the company managed to outperform against the industry average of 5.9%. Since the same quarter one year prior, revenues slightly dropped by 4.8%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
• Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, WARNER CHILCOTT PLC's return on equity significantly exceeds that of both the industry average and the S&P 500.
• The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Pharmaceuticals industry. The net income has significantly decreased by 26.2% when compared to the same quarter one year ago, falling from $71.85 million to $53.00 million.
• The debt-to-equity ratio is very high at 15.70 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Along with the unfavorable debt-to-equity ratio, WCRX maintains a poor quick ratio of 0.94, which illustrates the inability to avoid short-term cash problems.

Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. The company has a P/E ratio of 13.3, above the average drugs industry P/E ratio of 11.9 and below the S&P 500 P/E ratio of 17.7. Warner Chilcott has a market cap of $3.41 billion and is part of the health care sector and drugs industry. Shares are down 2.1% year to date as of the close of trading on Tuesday.

You can view the full Warner Chilcott Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

 

For more information on Warner Chilcott PLC click any of the following:

• Warner Chilcott PLC Stock Price

• Warner Chilcott PLC Analyst Ratings

• Warner Chilcott PLC Key Stats & Profile

• Warner Chilcott PLC Earnings

• Warner Chilcott PLC Ratio Comparison

• Warner Chilcott PLC Growth Rates

• Warner Chilcott PLC Balance Sheet

• Warner Chilcott PLC Cash Flow

• Warner Chilcott PLC Income Statement